CY1123061T1 - Μεθοδοι διαχωρισμου διαστερεοϊσομερων φωσφορικης γεμσιταβινης - Google Patents

Μεθοδοι διαχωρισμου διαστερεοϊσομερων φωσφορικης γεμσιταβινης

Info

Publication number
CY1123061T1
CY1123061T1 CY20201100477T CY201100477T CY1123061T1 CY 1123061 T1 CY1123061 T1 CY 1123061T1 CY 20201100477 T CY20201100477 T CY 20201100477T CY 201100477 T CY201100477 T CY 201100477T CY 1123061 T1 CY1123061 T1 CY 1123061T1
Authority
CY
Cyprus
Prior art keywords
phosphate
gemcitabine
diastereisomers
separation
methods
Prior art date
Application number
CY20201100477T
Other languages
English (en)
Inventor
Hugh GRIFFITH
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of CY1123061T1 publication Critical patent/CY1123061T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αυτή η αίτηση σχετίζεται με μια μέθοδο διαχωρισμού των φωσφορικών διαστερεοϊσομερών της [φαινυλο-βενζοξυ-L-αλανινυλο)]-φωσφορικής γεμσιταβίνης (NUC-I031) χρησιμοποιώντας κρυστάλλωση. Πιο συγκεκριμένα, η κρυστάλλωση από ισοπροπυλική αλκοόλη παρέχει [φαινυλο-βενζοξυ-L-αλανινυλο)]- (S)-φωσφορική γεμσιταβίνη σε υψηλή διαστερεοϊσομερικώς καθαρή μορφή. Αυτή η αίτηση σχετίζεται επίσης με μια κρυσταλλική μορφή της [φαινυλο-βενζοξυ-L-αλανινυλο)]- (S)-φωσφορικής γεμσιταβίνης.
CY20201100477T 2014-10-06 2020-05-25 Μεθοδοι διαχωρισμου διαστερεοϊσομερων φωσφορικης γεμσιταβινης CY1123061T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417644.0A GB201417644D0 (en) 2014-10-06 2014-10-06 Method of separating phosphate diastereoisomers
PCT/GB2015/052839 WO2016055769A1 (en) 2014-10-06 2015-09-29 Methods of separating gemcitabine-phosphate diastereoisomers

Publications (1)

Publication Number Publication Date
CY1123061T1 true CY1123061T1 (el) 2021-10-29

Family

ID=51946917

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100477T CY1123061T1 (el) 2014-10-06 2020-05-25 Μεθοδοι διαχωρισμου διαστερεοϊσομερων φωσφορικης γεμσιταβινης

Country Status (29)

Country Link
US (1) US10669300B2 (el)
EP (2) EP3204398B1 (el)
JP (2) JP6893172B2 (el)
KR (1) KR102532498B1 (el)
CN (2) CN107108682B (el)
AU (2) AU2015329767B2 (el)
CA (1) CA2959977C (el)
CL (1) CL2017000819A1 (el)
CY (1) CY1123061T1 (el)
DK (1) DK3204398T3 (el)
EA (1) EA033118B1 (el)
ES (1) ES2793957T3 (el)
GB (1) GB201417644D0 (el)
HR (1) HRP20200849T1 (el)
HU (1) HUE050882T2 (el)
IL (1) IL251125B (el)
LT (1) LT3204398T (el)
MA (1) MA41039B1 (el)
ME (1) ME03730B (el)
MX (2) MX2017004446A (el)
MY (1) MY183302A (el)
PH (1) PH12017500586A1 (el)
PL (1) PL3204398T3 (el)
PT (1) PT3204398T (el)
RS (1) RS60634B1 (el)
SG (2) SG11201701885UA (el)
SI (1) SI3204398T1 (el)
WO (1) WO2016055769A1 (el)
ZA (1) ZA201701723B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
MY176133A (en) 2012-11-16 2020-07-24 Nucana Biomed Ltd Process for preparing nucleoside prodrugs
TWI695718B (zh) 2014-06-25 2020-06-11 英商努卡那公眾有限公司 前藥
AU2015278900B2 (en) 2014-06-25 2019-04-04 NuCana plc Formulation comprising a gemcitabine-prodrug
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN112156102B (zh) * 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
JP7038653B2 (ja) 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法
AU2016367237B2 (en) 2015-12-11 2020-12-24 Laurus Labs Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
GB201522771D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN107400156B (zh) * 2017-09-19 2020-01-31 北京大学 一种分离麦角甾烷型三萜25r-与25s-差向异构体的方法
CN115028594A (zh) * 2020-06-03 2022-09-09 吴卫东 恩替他滨药用前体化合物及其制备方法和医学用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254092B1 (en) * 2000-02-11 2004-01-21 Degussa AG Resolution of dl-racemic mixtures
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
FR2954310B1 (fr) * 2009-12-18 2014-07-25 Univ Rouen Procede de dedoublement d'enantiomeres par evapocristallisation preferentielle
MY176133A (en) * 2012-11-16 2020-07-24 Nucana Biomed Ltd Process for preparing nucleoside prodrugs
WO2014204856A1 (en) 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
US10030044B2 (en) * 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
TWI695718B (zh) 2014-06-25 2020-06-11 英商努卡那公眾有限公司 前藥
AU2015278900B2 (en) * 2014-06-25 2019-04-04 NuCana plc Formulation comprising a gemcitabine-prodrug
CN106795198B (zh) 2014-07-22 2019-09-06 努卡那公共有限公司 用于制备吉西他滨-[苯基(苄氧基-l-丙氨酸基)]磷酸酯的方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3415149A1 (en) 2015-05-14 2018-12-19 NuCana plc Cancer treatments
JP7038653B2 (ja) 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法
AU2016367237B2 (en) 2015-12-11 2020-12-24 Laurus Labs Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
MX2018007772A (es) 2015-12-23 2019-07-04 NuCana plc Terapia de combinacion.
AU2015418015B2 (en) 2015-12-23 2021-12-09 NuCana plc Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative

Also Published As

Publication number Publication date
JP6893172B2 (ja) 2021-06-23
PL3204398T3 (pl) 2020-11-16
ZA201701723B (en) 2023-11-29
CL2017000819A1 (es) 2017-11-03
KR102532498B1 (ko) 2023-05-12
GB201417644D0 (en) 2014-11-19
IL251125B (en) 2020-07-30
AU2015329767B2 (en) 2020-03-12
AU2020203714B2 (en) 2021-07-22
AU2015329767A1 (en) 2017-04-13
US10669300B2 (en) 2020-06-02
JP2017530172A (ja) 2017-10-12
JP2020128392A (ja) 2020-08-27
ES2793957T3 (es) 2020-11-17
EP3204398A1 (en) 2017-08-16
PT3204398T (pt) 2020-05-28
SG11201701885UA (en) 2017-04-27
WO2016055769A1 (en) 2016-04-14
IL251125A0 (en) 2017-04-30
CN112552362A (zh) 2021-03-26
MX2020003758A (es) 2021-10-26
PH12017500586A1 (en) 2017-08-30
JP6967625B2 (ja) 2021-11-17
CA2959977A1 (en) 2016-04-14
DK3204398T3 (da) 2020-06-02
MA41039B1 (fr) 2020-08-31
CN107108682B (zh) 2020-12-18
MX2017004446A (es) 2017-06-19
EP3204398B1 (en) 2020-05-13
SI3204398T1 (sl) 2020-09-30
ME03730B (me) 2021-01-20
HRP20200849T1 (hr) 2020-10-30
CN107108682A (zh) 2017-08-29
CA2959977C (en) 2024-01-02
EA033118B1 (ru) 2019-08-30
HUE050882T2 (hu) 2021-01-28
LT3204398T (lt) 2020-09-10
EP3725794A1 (en) 2020-10-21
AU2020203714A1 (en) 2020-06-25
SG10201902952SA (en) 2019-05-30
BR112017006855A2 (pt) 2017-12-12
US20170226147A1 (en) 2017-08-10
EA201790794A1 (ru) 2017-07-31
MY183302A (en) 2021-02-18
KR20170090413A (ko) 2017-08-07
RS60634B1 (sr) 2020-09-30

Similar Documents

Publication Publication Date Title
CY1123061T1 (el) Μεθοδοι διαχωρισμου διαστερεοϊσομερων φωσφορικης γεμσιταβινης
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
BR112018010118A2 (pt) inibidores de cxcr2
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
CY1124587T1 (el) Μεθοδος για την παρασκευη toy brivaracetam
MX2018007782A (es) Forma cristalina de gemcitabina.
EA201692312A1 (ru) Продукты гемцитабина
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
EA201692288A1 (ru) Способ получения фосфорсодержащих циангидринов
MX2018002731A (es) Proceso para la elaboracion de esteres de cianohidrina que contienen fosforo.
EA201691006A1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
MX2017001459A (es) Sintesis de fosforamidatos.
MX2018002729A (es) Proceso para la elaboracion de esteres de cianohidrina que contienen fosforo.
NZ720106A (en) A process for the preparation of regadenoson
MX2018002730A (es) Proceso para producir esteres de cianhidrina que contienen fosforo.
BR112016028801A2 (pt) inibidores de moléculas pequenas de lfa-1
EA201691362A1 (ru) Способы получения конденсированных гетероциклических модуляторов ионных каналов
MX2018002726A (es) Proceso para producir esteres de cianhidrina que contienen fosforo.
EA201791329A1 (ru) Новые кристаллические формы мононатриевой соли форамсульфурона
MX2019005785A (es) Proceso para la purificacion de 1-(4-clorofenil)pirazol-3-ol.
BR112014012595A2 (pt) processo de racemização de ácido (s)-3-carbamoilmetil-5-metil-hexanoico
IN2014CH00444A (el)
MX2017012027A (es) Desaminacion de nucleosidos organofosforados.